Immunovant, Inc.
NASDAQ: IMVT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eric Venker
- Employees
- 362
- Headquarters
- New York City, United States
- IPO year
- 2019
- Market cap
- $7.3B
- Website
- https://immunovant.com
Loading IMVT…
Loading profile data…Frequently asked questions about IMVT
What does Immunovant, Inc. (IMVT) do?
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the n...
Where does IMVT trade?
Immunovant, Inc. (IMVT) trades on the NASDAQ Global Select.
What sector is IMVT in?
Immunovant, Inc. (IMVT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immunovant, Inc.?
Eric Venker is the chief executive officer of Immunovant, Inc. (IMVT).
Where is Immunovant, Inc. headquartered?
Immunovant, Inc. is headquartered in United States.
Does IMVT pay a dividend?
Immunovant, Inc. (IMVT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMVT go public?
Immunovant, Inc. (IMVT) completed its initial public offering in 2019.